Dutasteride added to anti-androgen treatment for salivary cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This Phase 2 trial studies whether adding dutasteride to standard anti-androgen therapy can shrink or slow an advanced salivary gland cancer. It is for cancers that test “androgen receptor (AR) positive,” meaning they may respond to medicines that block male-hormone signals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced salivary gland cancer that was proven on biopsy and is not curable
- Your tumor tests “AR positive” on a special lab test (at least 1% of cancer cells)
- You are 18 years or older and can sign informed consent
- Your health status is fairly good (ECOG 0 or 1) and you can swallow well enough for study medicine
- Your blood, liver, kidney, and heart function meet lab/health limits set by the study
- Your cancer has measurable disease that can be tracked by scan results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for advanced salivary gland cancer that has spread or cannot be removed with surgery. The drugs may block hormones and slow cancer growth, potentially helping people whose tumors have specific markers.
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Hear when a new Salivary Duct Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.